Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Michael G. Hanna, Umesh A. Badrising, Olivier Benveniste, Thomas E. Lloyd, Merrilee Needham, Hector Chinoy, Masashi Aoki, Pedro M. Machado, Christina Liang, Katrina A. Reardon, Marianne de Visser, Dana P. Ascherman, Richard J. Barohn, Mazen M. Dimachkie, James A.L. Miller, John T. Kissel, Björn Oskarsson, Nanette C. Joyce, P. Van den Bergh, Jonathan BaetsJ. L. De Bleecker, Chafic Karam, William S. David, Massimiliano Mirabella, Sharon P. Nations, Hans H. Jung, E. Pegoraro, Lorenzo Maggi, Carmelo Rodolico, Massimiliano Filosto, Aziz I. Shaibani, Kumaraswamy Sivakumar, Namita A. Goyal, Madoka Mori-Yoshimura, Satoshi Yamashita, N. Suzuki, Masahisa Katsuno, K. Murata, Hiroyuki Nodera, Ichizo Nishino, Carla D. Romano, Valerie S.L. Williams, John Vissing, Lixin Zhang Auberson, Min Wu, Ana de Vera, Dimitris A. Papanicolaou, Anthony A. Amato

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial'. Together they form a unique fingerprint.

Medicine & Life Sciences